Ainos (AIMD) 10-K 16 Apr 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Apr. 15, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Entity Central Index Key	0001014763
Trading Symbol	amar
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		39,453,524
Entity Public Float			$ 8,681,840
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 1,276,654	$ 2,038,150
Inventory		22,666
Prepaid expense and other current assets	26,580	23,635
Total current assets	1,303,234	2,084,451
Patents, net	146,456	182,386
Property and equipment, net	14,010	26,997
Total assets	1,463,700	2,293,834
Liabilities and Stockholders’ Deficit
Accounts payable and accrued expenses	115,313	159,300
Advances from investors	104,952	777,258
Convertible notes payable – related party	513,356	886,481
Total current liabilities	733,621	1,823,039
Total liabilities	733,621	1,823,039
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value: Authorized shares – 10,000,000, Issued and outstanding shares – 0 at December 31, 2018 and December 31, 2017, respectively
Common stock, $0.01 par value: Authorized shares – 100,000,000, Issued and outstanding shares –39,117,524 and 23,156,563 at December 31, 2018 and 2017, respectively	391,175	231,565
Additional paid-in capital	3,527,238	2,123,205
Accumulated deficit	(3,188,334)	(1,883,975)
Total stockholders’ equity	730,079	470,795
Total liabilities and stockholders’ equity	$ 1,463,700	$ 2,293,834

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	39,117,524	23,156,563
Common stock, shares outstanding (in shares)	39,117,524	23,156,563

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 77,724	$ 250,928
Cost of revenues	(64,877)	(60,316)
Gross margin	12,847	190,612
Operating expenses:
Research and development expenses	32,591
Selling, general and administrative expenses	1,314,932	770,375
Total operating expenses	1,347,523	770,375
Operating loss	(1,334,676)	(579,763)
Other income (expense):
Interest expense	(3,963)	(37,612)
Net loss	$ (1,338,639)	$ (617,375)
Basic and diluted net loss per average share available to common shareholders (in dollars per share)	$ (0.04)	$ (0.03)
Weighted average common shares outstanding – basic and diluted (in shares)	35,643,804	22,663,476

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016		21,916,143
Balance at Dec. 31, 2016		$ 219,161	$ 237,540	$ (1,266,600)	$ (809,899)
Issuance of stock for cash (in shares)		770,000
Issuance of stock for cash		$ 7,700	136,657		144,357
Issuance of stock for service (in shares)		57,000
Issuance of stock for service		$ 570	10,118		10,688
Issuance of stock for compensation (in shares)		413,420
Issuance of stock for compensation		$ 4,134	102,116		106,250
Conversion feature on Chen demand note			28,200		28,200
Stock subscription			1,608,574		1,608,574
Net loss for the year ended December 31				(617,375)	(617,375)
Balance (in shares) at Dec. 31, 2017		23,156,563
Balance at Dec. 31, 2017		$ 231,565	2,123,205	(1,883,975)	470,795
Issuance of stock for cash (in shares)		5,440,973
Issuance of stock for cash		$ 54,410	1,067,875		1,122,285
Issuance of stock for compensation (in shares)		451,480
Issuance of stock for compensation		$ 4,515	111,735		116,250
Net loss for the year ended December 31				(1,338,639)	(1,338,639)
Reversal of dividends on preferred stock				34,280	34,280
Issuance of stock for subscription (in shares)		8,579,061
Issuance of stock for subscription		$ 85,791	(85,791)
Issuance of stock for debt (in shares)		950,000
Issuance of stock for debt		$ 9,500	168,625		178,125
Acquisition of voting interest of ACTS (in shares)		539,447
Acquisition of voting interest of ACTS		$ 5,394	13,458		18,852
Warrant expense			27,765		27,765
Option expense			100,366		100,366
Balance (in shares) at Dec. 31, 2018		39,117,524
Balance at Dec. 31, 2018		$ 391,175	$ 3,527,238	$ (3,188,334)	$ 730,079

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from Operating Activities
Net loss	$ (1,338,639)	$ (617,375)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	56,194	39,990
Stock issued for services	27,765	10,688
Stock compensation	100,366	106,250
Amortization of debt discount		28,200
Changes in operating assets and liabilities:
Inventory	22,666	(7,966)
Prepaid expense and other current assets	67,400	89,939
Accounts payable and accrued expenses	54,844	(9,461)
Accrued interest – related party	206
Customer deposits		(124,833)
Net cash used in operating activities	(1,009,198)	(484,568)
Cash flows from Investing Activities
Investment in patents	(2,369)	(49,096)
Capital expenditures	(4,908)
Net cash used in investing activities	(7,277)	(49,096)
Cash flows from Financing Activities
Cash received from stock subscription		1,421,074
Proceeds from private placement offering, net	401,250	144,357
Advances from investors	48,729	777,258
Proceeds from convertible note payable – related party		95,000
Repayment on convertible note payable – related party	(195,000)
Net cash provided by financing activities	254,979	2,437,689
Net change in cash	(761,496)	1,904,025
Cash and cash equivalents at beginning of period	2,038,150	134,125
Cash and cash equivalents at end of period	1,276,654	2,038,150
Supplemental Cash Flow Information
Cash paid for interest	3,818	29,318
Cash paid for income taxes
Non-Cash Transactions
Stock issued for accrued liabilities	116,250
Stock issued for subscription	85,791
Conversion of debt to common stock	178,125
Reversal of accrued dividends	34,280
Stock issued for advances from investors	$ 721,035	$ 187,500

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Summary of Significant Accounting Policies Organization and Business Amarillo Biosciences, Inc. (the "Company" or "ABI"), is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. ABI is a Texas corporation which was formed in 1984. ABI primarily operates through three 1 2 Principles of Consolidation Effective January 1, 2018, 810, 810" July 1, 2018, 100% January 1, 2018. The Company applies the provisions of ASC 810 In general, a VIE is a corporation, partnership, limited-liability corporation, trust, or any other legal structure used to conduct activities or hold assets that either ( 1 2 3 not 4 not ASC 810 Going Concern These financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not no The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not There can be no may may may Fair Value of Financial Instruments Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three 1 3 ● Level 1, ● Level 2, not ● Level 3, no one Our Level 1 Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Cash and Cash Equivalents The Company classifies investments as cash equivalents if the original maturity of an investment is three Revenue Recognition n May 2014, 2014 09, August 2015, March 2016, April 2016, May 2016, December 2016 2015 14, 2016 08, 2016 10, 2016 12 2016 20, five two On January 1, 2018, 606 no no Results for reporting periods beginning after January 1, 2018 606, not 605, The Company's primary source of revenue is the sale of products within three The Medical division currently provides equipment to metabolism treatment centers in Taiwan and Hong Kong. Additionally, this division provides TissueAid TM The Pharmaceutical Division is currently seeking to leverage the Company's intellectual property and core technology, low-dose oral interferon, to expand treatment of the aforementioned neoplastic, viral, and fibrotic diseases as well as other potential indications. Revenue recognized during the year ended December 31, 2018 50% 2018 one December 31, 2017 one Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not one no no December 31, 2018 2017. $7,320 2018. Inventory Inventories are stated at the lower of cost or market. Cost is determined on a first first Property and Equipment Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two seven Patents and Patent Expenditures ABI holds patent license agreements and holds patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 20 December 31, 2018, $16,000 Long-lived Assets Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No Income Taxes The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not Research and Development Research and development costs are expensed as incurred. During the year ended December 31, 2018, $32,591 Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and Diluted Net Income ( Loss ) Per Share As of December 31, 2018, 3,458,214 not Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single financial institution which, from time to time, could exceed the federally insured limit of $250,000. No Recent Accounting Pronouncements In February 2016, No. 2016 02 2016 02 842 2016 02 12 2016 02 2016 02 2016 02 December 15, 2018, 2016 02 not In June 2018, 2018 07, 718 2018 07” 2018 07 718 2018 07 718 not 1 2 606 2018 07 December 15, 2018, 2018 07 January 1, 2019. 2018 07 not Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not not

Note 2 - Property, Equipment an

Note 2 - Property, Equipment and Software, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	2. Property, equipment and software are stated at cost less accumulated depreciation and consist of the following at December 31, 2018 2017: 2018 2017 Furniture and equipment $ 92,988 $ 92,988 Automobiles 4,911 - Software 8,012 8,012 105,911 101,000 Less: accumulated depreciation (91,901 ) (74,003 ) Property, equipment and software, net $ 14,010 $ 26,997 Depreciation expense amounted to $17,895 December 31, 2018 $17,217 December 31, 2017

Note 3 - Patents, Net

Note 3 - Patents, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	3. Patents are stated at cost less accumulated amortization and consist of the following at December 31, 2018 2017: 2018 2017 Patents $ 228,669 $ 338,324 Less: accumulated amortization (82,213 ) (155,938 ) Patents, net $ 146,456 $ 182,386 During the year ended December 31, 2018, $112,022 $96,055 $15,967 Amortization expense amounted to $38,296 December 31, 2018 $22,773 December 31, 2017, Estimated future amortization expense is as follows: 2019 11,582 2020 11,494 2021 9,838 2022 9,434 Thereafter 104,108 Total expense $ 146,456

Note 4 - Convertible Notes Paya

Note 4 - Convertible Notes Payable - Related Party	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	4. As of December 31, 2018 2017, $513,356 $886,481, December 31, 2018 December 31, 2017 Convertible Note payable – related party $ 144,426 $ 144,426 Convertible Note payable – related party 262,500 262,500 Convertible Note payable – related party 106,430 384,555 Convertible Note payable – related party - 70,000 Convertible Note payable – related party - 25,000 Convertible Notes payable – related party $ 513,356 $ 886,481 On January 8, 2018, $25,000 $25,000, $84. On March 8, 2018, $70,000 $70,000, $474. On March 9, 2018, $384,555. $100,000 $100,000, $3,260. On April 1, 2018, $178,125 $284,555 April 2, 2018 April 6, 2018, 550,000 400,000 $0.1875 $106,430. As of December 31, 2018, Note #. Date Payee Principal Amount Maturity Annual Interest AFR 2 Conversion Price 1 1/11/2016 Stephen T.Chen $144,426 On Demand 0.75% $0.1680 2 3/18/2016 Stephen T. Chen $262,500 On Demand 0.65% $0.1875 3 6/30/2016 Stephen T. Chen $106,430 On Demand 0.64% $0.1875 Total Convertible Notes Payable $513,356 All of the Notes are unsecured. The Notes are convertible into ABI Common Voting Shares which are issued as restricted stock pursuant to SEC Rule 144.

Note 5 - ACTS Global

Note 5 - ACTS Global	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Variable Interest Entity Disclosure [Text Block]	5 . ACTS Global On May 23, 2016, may may one 1% 2 Since the inception of the Agency Agreement in 2016, no January 1, 2018 2017, December 31, 2017 $58,135 On June 18, 2018, July 1, 2018, 539,447 July 12, 2018, 539,447 Shareholder/Recipient Issue Date Number of Shares Seu Chi Kuo July 12, 2018 179,852 Po Ya Tseng July 12, 2018 179,852 Yasushi Chikagami July 12, 2018 53,891 Stephen/Virginia Chen Living Trust July 12, 2018 125,852 Total 539,447

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6. On February 2, 2018, 1,000,000 $0.1875 $187,500 March 18, 2016, April 7, 2016. On March 27, 2018, January 1, 2018, $240,000 $100,000 $70,000 $12,000 15th 31st first December 31, 2018, 86,698 $21,250 fourth 2017 364,782 $95,000 second third 2018. On July 12, 2018, 125,852

Note 7 - Common Stock

Note 7 - Common Stock	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. The Company has 100,000,000 December 31, 2018 47,973,355 39,117,524 8,855,831 On January 3, 2017, 145,405 19,387 2016 $42,500. $.2579 December 20, 2016. December 31, 2016. During 2017, 413,420 $106,250. During 2017, 770,000 $144,357. 200,000 $.1875 $37,500. On August 1, 2017, 57,000 $.1875 $10,688. During 2017, 8,579,061 $0.1875 $1,608,574. 2018. During 2018, 3,740,973 $721,035 2017 2017 During 2018, 1,700,000 $401,250. During 2018, 451,480 $116,250. On April 1, 2018, $178,125 950,000 $.1875 Effective July 1, 2018, 539,447

Note 8 - Preferred Stock

Note 8 - Preferred Stock	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Preferred Stock [Text Block]	8. The shareholders have authorized 10,000,000 No December 31, 2018 2017 none

Note 9 - Stock Option and Stock

Note 9 - Stock Option and Stock Plans	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9 . Stock Option and Stock Plans On September 26, 2018, 2018 “2018 may 2018 six million 6,000,000 $0.38 ten 10 20% five 5 one 1 ten 10% 424 110% $0.418; five 5 ten 10 five 5 four 4 On September 26, 2018, 2018 “2018 may 2018 twenty million 20,000,000 $0.38 ten 10 five 5 20% one 1 no ten 10% Equity Compensation Plan Information: Stock Plans 1 Issue Date Range Total Shares Authorized Shares Issued Shares Remaining 2008 Stock Incentive Plan 5/23/08 – 10/11/11 600,000 463,420 136,580 Amarillo Biosciences, Inc., 2018 Employee Stock Option Plan 9/26/18 – 9/26/28 6,000,000 950,000 5,050,000 Amarillo Biosciences, Inc., 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan 9/26/18 – 9/26/28 20,000,000 3,995,000 16,005,000 1 Whether qualified or nonqualified, when options are exercised the ABI Common Stock shares will be issued pursuant to Rule 144A six A summary of option activity for the years ended December 31, 2018 2017 Date Number of Options Qualified Number of Options Nonqualified Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance December 31, 2017 - - - - - Granted September 26, 2018* *950,000 3,995,000 $0.38 5 Exercised - - - - - Expired - - - - - Balance December 31, 2018* *950,000 3,995,000 $0.38 5 * There is one 10% 500,000 $0.418 5 4 25% The Company used the Black-Scholes option pricing model to value the option awards with the following assumptions applied: ( 1 276%; 2 5 10 5 3 2.96%. December 31, 2018, $1,775,222 4.75

Note 10 - Warrants

Note 10 - Warrants	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Warrant Disclosure [Text Block]	10. On April 15, 2018, 452,617 $0.27 April 14, 2020. $75,967 twenty-four 1 207%; 2 2 3 2.39%. No 2018 2017.

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income tax expense (benefit) attributable to income from continuing operations differed from the amounts computed by applying the U.S. Federal income tax of 21% 2018 34% 2017 December 31, 2018 December 31, 2017 Provision (benefit) at statutory rate $ (281,000 ) $ (210,000 ) Effect of rate change on deferred assets - 3,010,000 Change in valuation allowance 281,000 (2,800,000 ) $ - $ - The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2018 2017, December 31, 2018 December 31, 2017 Deferred tax assets: Net operating loss carryforward $ 5,082,000 $ 4,801,000 Deferred tax assets 5,082,000 4,801,000 Deferred tax liabilities: - - Net deferred tax assets 5,082,000 4,801,000 Valuation allowance (5,082,000 ) (4,801,000 ) $ - $ - At December 31, 2018, $24,204,000 2018 2036. may not 3 not no As of December 31, 2018, 2018, 2017 2016

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 2 . Commitments and Contingencies Lease commitment Our executive and administrative offices are located at 4134 1,800 July 1 June 30 December 31, 2018 $1,120 June 30, 2019. Litigation The Company is not not December 31, 2018. 3 26 382 382 Officer Compensation On March 28, 2018, three $240,000 $100,000 $70,000 $12,000 may may Each contract provides that the Employee shall devote his entire productive time, ability, attention and energies to the business of the Company. In addition, the contracts protect the property rights of the Company, including inventions and other intellectual property, trade secrets, and proprietary information. The contracts also prohibit Employee from competing directly or indirectly with the business of the Company or its controlled subsidiaries, both during the term of the contracts, and continuing for a period of three not

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	1 3 . Subsequent Events In February 2019, 200,000 $0.25 2016 3 February 2019, 136,000 fourth 2018

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation Effective January 1, 2018, 810, 810" July 1, 2018, 100% January 1, 2018. The Company applies the provisions of ASC 810 In general, a VIE is a corporation, partnership, limited-liability corporation, trust, or any other legal structure used to conduct activities or hold assets that either ( 1 2 3 not 4 not ASC 810
Going Concern Policy [Policy Text Block]	Going Concern These financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not no The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not There can be no may may may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three 1 3 ● Level 1, ● Level 2, not ● Level 3, no one Our Level 1
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company classifies investments as cash equivalents if the original maturity of an investment is three
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition n May 2014, 2014 09, August 2015, March 2016, April 2016, May 2016, December 2016 2015 14, 2016 08, 2016 10, 2016 12 2016 20, five two On January 1, 2018, 606 no no Results for reporting periods beginning after January 1, 2018 606, not 605, The Company's primary source of revenue is the sale of products within three The Medical division currently provides equipment to metabolism treatment centers in Taiwan and Hong Kong. Additionally, this division provides TissueAid TM The Pharmaceutical Division is currently seeking to leverage the Company's intellectual property and core technology, low-dose oral interferon, to expand treatment of the aforementioned neoplastic, viral, and fibrotic diseases as well as other potential indications. Revenue recognized during the year ended December 31, 2018 50% 2018 one December 31, 2017 one
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not one no no December 31, 2018 2017. $7,320 2018.
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or market. Cost is determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Patent Expenditures ABI holds patent license agreements and holds patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 20 December 31, 2018, $16,000
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-lived Assets Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred. During the year ended December 31, 2018, $32,591
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Income ( Loss ) Per Share As of December 31, 2018, 3,458,214 not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single financial institution which, from time to time, could exceed the federally insured limit of $250,000. No
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, No. 2016 02 2016 02 842 2016 02 12 2016 02 2016 02 2016 02 December 15, 2018, 2016 02 not In June 2018, 2018 07, 718 2018 07” 2018 07 718 2018 07 718 not 1 2 606 2018 07 December 15, 2018, 2018 07 January 1, 2019. 2018 07 not Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not not

Note 2 - Property, Equipment _2

Note 2 - Property, Equipment and Software, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	2018 2017 Furniture and equipment $ 92,988 $ 92,988 Automobiles 4,911 - Software 8,012 8,012 105,911 101,000 Less: accumulated depreciation (91,901 ) (74,003 ) Property, equipment and software, net $ 14,010 $ 26,997

Note 3 - Patents, Net (Tables)

Note 3 - Patents, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2018 2017 Patents $ 228,669 $ 338,324 Less: accumulated amortization (82,213 ) (155,938 ) Patents, net $ 146,456 $ 182,386
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2019 11,582 2020 11,494 2021 9,838 2022 9,434 Thereafter 104,108 Total expense $ 146,456

Note 4 - Convertible Notes Pa_2

Note 4 - Convertible Notes Payable - Related Party (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	December 31, 2018 December 31, 2017 Convertible Note payable – related party $ 144,426 $ 144,426 Convertible Note payable – related party 262,500 262,500 Convertible Note payable – related party 106,430 384,555 Convertible Note payable – related party - 70,000 Convertible Note payable – related party - 25,000 Convertible Notes payable – related party $ 513,356 $ 886,481
Schedule of Convertible Notes Payable, Related Parties [Table Text Block]	Note #. Date Payee Principal Amount Maturity Annual Interest AFR 2 Conversion Price 1 1/11/2016 Stephen T.Chen $144,426 On Demand 0.75% $0.1680 2 3/18/2016 Stephen T. Chen $262,500 On Demand 0.65% $0.1875 3 6/30/2016 Stephen T. Chen $106,430 On Demand 0.64% $0.1875 Total Convertible Notes Payable $513,356

Note 5 - ACTS Global (Tables)

Note 5 - ACTS Global (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Issuance of Common Stock for Acquisition [Table Text Block]	Shareholder/Recipient Issue Date Number of Shares Seu Chi Kuo July 12, 2018 179,852 Po Ya Tseng July 12, 2018 179,852 Yasushi Chikagami July 12, 2018 53,891 Stephen/Virginia Chen Living Trust July 12, 2018 125,852 Total 539,447

Note 9 - Stock Option and Sto_2

Note 9 - Stock Option and Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Plans 1 Issue Date Range Total Shares Authorized Shares Issued Shares Remaining 2008 Stock Incentive Plan 5/23/08 – 10/11/11 600,000 463,420 136,580 Amarillo Biosciences, Inc., 2018 Employee Stock Option Plan 9/26/18 – 9/26/28 6,000,000 950,000 5,050,000 Amarillo Biosciences, Inc., 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan 9/26/18 – 9/26/28 20,000,000 3,995,000 16,005,000
Employee Stock Option [Member]
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Date Number of Options Qualified Number of Options Nonqualified Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance December 31, 2017 - - - - - Granted September 26, 2018* *950,000 3,995,000 $0.38 5 Exercised - - - - - Expired - - - - - Balance December 31, 2018* *950,000 3,995,000 $0.38 5

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	December 31, 2018 December 31, 2017 Provision (benefit) at statutory rate $ (281,000 ) $ (210,000 ) Effect of rate change on deferred assets - 3,010,000 Change in valuation allowance 281,000 (2,800,000 ) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2018 December 31, 2017 Deferred tax assets: Net operating loss carryforward $ 5,082,000 $ 4,801,000 Deferred tax assets 5,082,000 4,801,000 Deferred tax liabilities: - - Net deferred tax assets 5,082,000 4,801,000 Valuation allowance (5,082,000 ) (4,801,000 ) $ - $ -

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)	Jul. 01, 2018
Allowance for Doubtful Accounts Receivable, Ending Balance	$ 0	$ 0
Number of Operating Segments	3
Allowance for Doubtful Accounts Receivable, Write-offs	$ 7,320
Write Off of Patent Costs	16,000
Impairment of Long-Lived Assets Held-for-use	0
Research and Development Expense, Total	$ 32,591
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	3,458,214
Cash, FDIC Insured Amount	$ 250,000
Minimum [Member]
Property, Plant and Equipment, Useful Life	2 years
Minimum [Member] | Patents [Member]
Finite-Lived Intangible Asset, Useful Life	15 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Number of Major Customers	1	1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | One Customer [Member]
Concentration Risk, Percentage	50.00%
ACTS Global Healthcare, Inc. [Member]
Business Acquisition, Percentage of Voting Interests Acquired			100.00%

Note 2 - Property, Equipment _3

Note 2 - Property, Equipment and Software, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 17,895	$ 17,217

Note 2 - Property, Equipment _4

Note 2 - Property, Equipment and Software, Net - Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, plant and equipment, gross	$ 105,911	$ 101,000
Less: accumulated depreciation	(91,901)	(74,003)
Property, equipment and software, net	14,010	26,997
Furniture and Fixtures [Member]
Property, plant and equipment, gross	92,988	92,988
Automobiles [Member]
Property, plant and equipment, gross	4,911
Software and Software Development Costs [Member]
Property, plant and equipment, gross	$ 8,012	$ 8,012

Note 3 - Patents, Net (Details

Note 3 - Patents, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Payments to Acquire Intangible Assets	$ 2,369	$ 49,096
Amortization of Intangible Assets, Total	38,296	$ 22,773
Patents [Member]
Payments to Acquire Intangible Assets	112,022
Write Off of Intangible Assets Due to Obsolete Status	96,055
Amortization of Intangible Assets, Total	$ 15,967

Note 3 - Patents, Net - Patents

Note 3 - Patents, Net - Patents (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Patents	$ 146,456	$ 182,386
Patents, net	146,456
Patents [Member]
Patents	228,669	338,324
Less: accumulated amortization	(82,213)	(155,938)
Patents, net	$ 146,456	$ 182,386

Note 3 - Patents, Net - Estimat

Note 3 - Patents, Net - Estimated Future Amortization Expense (Details)	Dec. 31, 2018USD ($)
2019	$ 11,582
2020	11,494
2021	9,838
2022	9,434
Thereafter	104,108
Total expense	$ 146,456

Note 4 - Convertible Notes Pa_3

Note 4 - Convertible Notes Payable - Related Party (Details Textual) - USD ($)	Apr. 06, 2018	Apr. 02, 2018	Apr. 01, 2018	Mar. 09, 2018	Mar. 08, 2018	Jan. 18, 2018	Dec. 31, 2018	Feb. 02, 2018	Jan. 08, 2018	Dec. 31, 2017
Notes Payable, Convertible, Related Parties, Classified Current							$ 513,356			$ 886,481
Chief Executive Officer [Member]
Notes Payable, Convertible, Related Parties, Classified Current				$ 384,555	$ 70,000		513,356		$ 25,000	886,481
Repayments of Related Party Debt				100,000	70,000	$ 25,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total				$ 3,260	$ 474	$ 84
Debt Conversion, Converted Instrument, Amount			$ 178,125
Debt Conversion, Converted Instrument, Shares Issued	400,000	550,000	950,000
Shares Issued, Price Per Share	$ 0.1875	$ 0.1875	$ 0.1875					$ 0.1875
Chief Executive Officer [Member] | Third Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	$ 106,430		$ 284,555				$ 106,430			$ 384,555

Note 4 - Convertible Notes Pa_4

Note 4 - Convertible Notes Payable - Related Party - Related Party Transactions, Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2018	Apr. 06, 2018	Apr. 01, 2018	Mar. 09, 2018	Mar. 08, 2018	Jan. 08, 2018	Dec. 31, 2017
Convertible Note payable – related party	$ 513,356						$ 886,481
Chief Executive Officer [Member]
Convertible Note payable – related party	513,356			$ 384,555	$ 70,000	$ 25,000	886,481
Chief Executive Officer [Member] | First Issuance [Member]
Convertible Note payable – related party	144,426						144,426
Chief Executive Officer [Member] | Second Issuance [Member]
Convertible Note payable – related party	262,500						262,500
Chief Executive Officer [Member] | Third Issuance [Member]
Convertible Note payable – related party	106,430	$ 106,430	$ 284,555				384,555
Chief Executive Officer [Member] | Fourth Issuance [Member]
Convertible Note payable – related party							70,000
Chief Executive Officer [Member] | Fifth Issuance [Member]
Convertible Note payable – related party							$ 25,000

Note 4 - Convertible Notes Pa_5

Note 4 - Convertible Notes Payable - Related Party - Convertible Notes Payable Outstanding (Details)	Dec. 31, 2018USD ($)$ / shares
Principal amount	$ 513,356
Convertible Note Payable Number One [Member]
Principal amount	$ 144,426
Convertible Note Payable Number One [Member] | Related Party Convertible Notes Payable [Member]
Annual interest	0.75%	[1]
Conversion price (in dollars per share) | $ / shares	$ 0.168
Convertible Note Payable Number Two [Member]
Principal amount	$ 262,500
Convertible Note Payable Number Two [Member] | Related Party Convertible Notes Payable [Member]
Annual interest	0.65%	[1]
Conversion price (in dollars per share) | $ / shares	$ 0.1875
Convertible Note Payable Number Three [Member]
Principal amount	$ 106,430
Convertible Note Payable Number Three [Member] | Related Party Convertible Notes Payable [Member]
Annual interest	0.64%	[1]
Conversion price (in dollars per share) | $ / shares	$ 0.1875
[1]	Short Term Applicable Federal Rate

Note 5 - ACTS Global (Details T

Note 5 - ACTS Global (Details Textual) - USD ($)	Jul. 12, 2018	Jul. 01, 2018	Dec. 31, 2017	May 23, 2016
Stock Issued During Period, Shares, Acquisitions	539,447
ACTS Global Healthcare, Inc. [Member]
Increase (Decrease) in Prepaid Expense			$ (58,135)
Cash, Period Increase (Decrease), Total			$ 58,135
ACTS Global Healthcare, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions	539,447	539,447
ACTS Global Healthcare, Inc. [Member] | Variable Interest Entity, Primary Beneficiary [Member]
Percentage to be Paid to Affiliate for Services Rendered				1.00%

Note 5 - ACTS Global - Voting S

Note 5 - ACTS Global - Voting Shares Issued (Details)	Jul. 12, 2018shares
Stock Issued During Period, Shares, Acquisitions	539,447
Seu Chi Kuo [Member]
Stock Issued During Period, Shares, Acquisitions	179,852
Po Ya Tseng [Member]
Stock Issued During Period, Shares, Acquisitions	179,852
Yasushi Chikagami [Member]
Stock Issued During Period, Shares, Acquisitions	53,891
Stephen/Virginia Chen Living Trust [Member]
Stock Issued During Period, Shares, Acquisitions	125,852

Note 6 - Related Party Transa_2

Note 6 - Related Party Transactions (Details Textual) - USD ($)	Jul. 12, 2018	Mar. 28, 2018	Feb. 02, 2018	Jan. 01, 2018	Dec. 31, 2017	Sep. 30, 2018	Apr. 06, 2018	Apr. 02, 2018	Apr. 01, 2018
Stock Issued During Period, Shares, Acquisitions	539,447
Stephen/Virginia Chen Living Trust [Member]
Stock Issued During Period, Shares, Acquisitions	125,852
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues			1,000,000
Shares Issued, Price Per Share			$ 0.1875				$ 0.1875	$ 0.1875	$ 0.1875
Common Stock, Value, Subscriptions			$ 187,500
Officer Compensation, Annual Compensation, Cash		$ 240,000		$ 240,000
Officer Compensation, Annual Compensation, Share Value		100,000		100,000
Chief Financial Officer [Member]
Officer Compensation, Annual Compensation, Cash		70,000		70,000
Officer Compensation, Annual Compensation, Share Value		$ 12,000		$ 12,000
CEO and CFO [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross					86,698	364,782
Stock Issued During Period, Value, Share-based Compensation, Gross					$ 21,250	$ 95,000

Note 7 - Common Stock (Details

Note 7 - Common Stock (Details Textual) - USD ($)	Jul. 12, 2018	Jul. 01, 2018	Apr. 06, 2018	Apr. 02, 2018	Apr. 01, 2018	Feb. 02, 2018	Aug. 01, 2017	Jan. 03, 2017	Dec. 31, 2018	Dec. 31, 2017
Common Stock, Shares Authorized									100,000,000	100,000,000
Common Stock, Shares Outstanding and Reserved									47,973,355
Common Stock, Shares, Outstanding, Ending Balance									39,117,524	23,156,563
Deferred Compensation Arrangement with Individual, Shares Issued									451,480	413,420
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued									$ 116,250	$ 106,250
Proceeds from Issuance of Private Placement									401,250	144,357
Stock Issued During Period, Value, Issued for Services										10,688
Debt Conversion, Original Debt, Amount									$ 178,125
Stock Issued During Period, Shares, Acquisitions	539,447
ACTS Global Healthcare, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions	539,447	539,447
Private Placement [Member]
Stock Issued During Period, Shares, New Issues										770,000
Proceeds from Issuance of Private Placement										$ 144,357
Subscription Agreement [Member]
Common Stock, Shares Subscribed but Unissued										8,579,061
Share Price										$ 0.1875
Common Stock, Value, Subscriptions										$ 1,608,574
First Issuance to Investors [Member]
Stock Issued During Period, Shares, New Issues									3,740,973
Proceeds from Issuance of Private Placement									$ 721,035
Second Issuance to Investors [Member]
Stock Issued During Period, Shares, New Issues									1,700,000
Proceeds from Issuance of Private Placement									$ 401,250
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued								145,405
Shares Issued, Price Per Share			$ 0.1875	$ 0.1875	$ 0.1875	$ 0.1875
Stock Issued During Period, Shares, New Issues						1,000,000
Proceeds from Issuance of Private Placement										$ 37,500
Common Stock, Value, Subscriptions						$ 187,500
Debt Conversion, Original Debt, Amount					$ 178,125
Debt Conversion, Converted Instrument, Shares Issued			400,000	550,000	950,000
Chief Executive Officer [Member] | Private Placement [Member]
Shares Issued, Price Per Share										$ 0.1875
Stock Issued During Period, Shares, New Issues										200,000
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued								19,387
The Chief Executive Officer and Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued								$ 42,500
Shares Issued, Price Per Share								$ 0.2579
Finders [Member]
Shares Issued, Price Per Share							$ 0.1875
Stock Issued During Period, Shares, Issued for Services							57,000
Stock Issued During Period, Value, Issued for Services							$ 10,688
Debt Convertible to Common Stock [Member]
Common Stock, Capital Shares Reserved for Future Issuance									8,855,831

Note 8 - Preferred Stock (Detai

Note 8 - Preferred Stock (Details Textual) - shares	Apr. 15, 2019	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock, Shares Authorized		10,000,000	10,000,000
Preferred Stock, Shares Outstanding, Ending Balance		0	0
Subsequent Event [Member]
Preferred Stock, Shares Outstanding, Ending Balance	0

Note 9 - Stock Option and Sto_3

Note 9 - Stock Option and Stock Plans (Details Textual) - USD ($)	Sep. 26, 2018	Dec. 31, 2018		Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		276.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Discount Rate		2.96%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 1,775,222
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		4 years 273 days
Qualified Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000
Stock Option, Exercise Price	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		950,000	[1]
Qualified Options [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Stock Option, Exercise Price		$ 0.418
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		500,000
Qualified Options [Member] | If Option Grantee Owns or Controls Over Ten Percent of Outstanding Stock [Member]
Stock Option, Exercise Price	$ 0.418
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Stock Option Price, Percent	110.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche One [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Two [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Three [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Four [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	20,000,000
Stock Option, Exercise Price	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		3,995,000
Nonqualified Options [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
[1]	There is one stock owner over 10% currently holding 500,000 qualified options. The exercise price for this option-holder would be $0.418 with an exercise period of 5 years and a vesting period of 4 years at 25% per year.

Note 9 - Stock Option and Sto_4

Note 9 - Stock Option and Stock Plans - Stock Option Plan Summary (Details)	12 Months Ended
	Dec. 31, 2018shares	[1]
2008 Stock Incentive Plan [Member]
Total Shares Authorized (in shares)	600,000
Shares Issued (in shares)	463,420
Shares Remaining (in shares)	136,580
2018 Employee Stock Option Plan [Member]
Total Shares Authorized (in shares)	6,000,000
Shares Issued (in shares)	950,000
Shares Remaining (in shares)	5,050,000
2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan [Member]
Total Shares Authorized (in shares)	20,000,000
Shares Issued (in shares)	3,995,000
Shares Remaining (in shares)	16,005,000
[1]	The Board of Directors has approved all stock, stock option and stock warrant issuances.

Note 9 - Stock Option and Sto_5

Note 9 - Stock Option and Stock Plans - Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Weighted Average Exercise Price, Outstanding (in dollars per share) | $ / shares
Weighted Average Exercise Price, Granted (in dollars per share) | $ / shares	$ 0.38	[1]
Weighted Average Remaining Contractual Term, Granted (Year)	5 years	[1]
Weighted Average Exercise Price, Outstanding (in dollars per share) | $ / shares	$ 0.38
Weighted Average Remaining Contractual Term, Outstanding (Year)	5 years
Aggregate Intrinsic Value, Outstanding | $
Qualified Options [Member]
Number of Options, Outstanding (in shares)
Number of Options, Granted (in shares)	950,000	[1]
Number of Options, Exercised (in shares)
Number of Options, Expired (in shares)
Number of Options, Outstanding (in shares)	950,000	[1]
Nonqualified Options [Member]
Number of Options, Outstanding (in shares)
Number of Options, Granted (in shares)	3,995,000	[1]
Number of Options, Exercised (in shares)
Number of Options, Expired (in shares)
Number of Options, Outstanding (in shares)	3,995,000
[1]	There is one stock owner over 10% currently holding 500,000 qualified options. The exercise price for this option-holder would be $0.418 with an exercise period of 5 years and a vesting period of 4 years at 25% per year.

Note 10 - Warrants (Details Tex

Note 10 - Warrants (Details Textual)	12 Months Ended
	Dec. 31, 2018yrshares	Dec. 31, 2017shares	Apr. 15, 2018USD ($)$ / sharesshares
Class Of Warrant Or Right, Exercised	0	0
Warrants Issued to Consultants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			452,617
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.27
Warrants and Rights Outstanding | $			$ 75,967
Warrants and Rights Outstanding, Term			2 years
Warrants Issued to Consultants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	2.07
Warrants Issued to Consultants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	2
Warrants Issued to Consultants [Member] | Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0239

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Operating Loss Carryforwards, Total	$ 24,204,000
Open Tax Year	2018 2017 2016

Note 11 - Income Taxes - Income

Note 11 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Provision (benefit) at statutory rate	$ (281,000)	$ (210,000)
Effect of rate change on deferred assets		3,010,000
Change in valuation allowance	281,000	(2,800,000)

Note 11 - Income Taxes - Deferr

Note 11 - Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carryforward	$ 5,082,000	$ 4,801,000
Deferred tax assets	5,082,000	4,801,000
Deferred tax liabilities:
Net deferred tax assets	5,082,000	4,801,000
Valuation allowance	(5,082,000)	(4,801,000)

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual)	Mar. 28, 2018USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2018USD ($)ft²
Chief Executive Officer [Member]
Officer Compensation, Annual Compensation, Cash	$ 240,000	$ 240,000
Officer Compensation, Annual Compensation, Share Value	100,000	100,000
Chief Financial Officer [Member]
Officer Compensation, Annual Compensation, Cash	70,000	70,000
Officer Compensation, Annual Compensation, Share Value	$ 12,000	$ 12,000
Executive and Administrative Offices [Member]
Area of Real Estate Property | ft²			1,800
Operating Leases Rent Expense Monthly Amount			$ 1,120

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - $ / shares	1 Months Ended	12 Months Ended
	Feb. 28, 2019	Dec. 31, 2017
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		770,000
Subsequent Event [Member] | Dr. Stephen Chen, Bernard Cohen, and Lawrence Lin [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross	136,000
Subsequent Event [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues	200,000
Shares Issued, Price Per Share	$ 0.25